高级别B细胞淋巴瘤与弥漫性大B细胞淋巴瘤CAR-T细胞治疗结局的加权对比分析
该前瞻性队列纳入432例患者(HGBL 78例,DLBCL 354例),比较CAR-T治疗后的结局。加权后HGBL与DLBCL的2年总生存率分别为37%与44%(P=0.0343),差异与CAR-T治疗失败后生存较差相关。HGBL-DH/TH与其他高级别组织学类型间无进展生存和总生存无显著差异。
要点
- 加权后HGBL与DLBCL的2年总生存率分别为37%与44%,差异有统计学意义。
- HGBL-DH/TH与其他高级别组织学类型间的无进展生存和总生存无显著差异。
- CAR-T治疗失败后1年总生存率:转化型DLBCL 59%、原发DLBCL 32%、HGBL 11%。
核心结论
- 加权后HGBL与DLBCL的2年总生存率差异仍有统计学意义(37% vs 44%,P=0.0343),且与CAR-T治疗失败后生存较差相关。
- HGBL-DH/TH淋巴瘤与其他高级别组织学类型患者的无进展生存和总生存无统计学显著差异。
- HGBL中CAR-T细胞扩增与疗效不相关。
研究设计与样本
- 前瞻性研究队列,共432例患者,其中HGBL 78例、DLBCL 354例。
- HGBL中位随访22.8个月,DLBCL中位随访18个月。
- 采用加权log-rank检验和加权Cox模型评估亚型(HGBL vs DLBCL)的预测价值及CAR-T治疗失败后的总生存。
- 试验注册于www.clinicaltrials.gov,注册号NCT06339255。
主要发现
- 加权前HGBL与DLBCL的总生存差异有统计学意义(24个月总生存率:37% vs 49%,P=0.0036)。
- 加权后2年总生存率差异仍有统计学意义(HGBL 37% vs DLBCL 44%,P=0.0343),与CAR-T治疗失败后生存较差相关。
- HGBL-DH/TH与其他高级别组织学类型间的无进展生存和总生存无统计学显著差异。
- HGBL中CAR-T细胞扩增与疗效不相关。
- 2年非复发死亡率和第二恶性肿瘤发生率在HGBL与DLBCL中相似(11% vs 11%,P=0.830;6.4% vs 11.4%,P=0.844)。
临床怎么用
- 作者认为,更早使用CAR-T细胞治疗可能改善HGBL的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade B-cell lymphomas (HGBL, including double-hit/triple-hit [HGBL-DH/TH], and HGBL not otherwise specified) have a poor prognosis upon failure of first-line therapy. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for third-line aggressive large B-cell lymphomas (LBCL) resulted in long-term remission in ≤40% of patients. This study evaluated factors that can predict outcomes in HGBL compared to diffuse LBCL (DLBCL). We assessed the predictive value of the subtype (HGBL vs DLBCL) using weighted log-rank tests and weighted Cox models, and overall survival (OS) following CAR T-cell therapy failure. The prospective study cohort comprised 432 patients (HGBL, n = 78; DLBCL, n = 354), median follow-up of 22.8 months for HGBL and 18 months for DLBCL. Interestingly, there was no statistically significant difference in progression-free survival and OS between patients with HGBL-DH/TH lymphomas vs other high-grade histotypes. CAR T-cell therapy expansion in HGBL did not correlate with response. Before weighting, a significant difference in OS was observed between HGBL vs DLBCL (24-month OS: 37% vs 49%, P = .0036). After weighting, the difference in 2-year OS remained significant (37% vs 44%, P = .0343), and it was related to inferior survival following CAR T-cell therapy failure. The 2-year nonrelapse mortality and incidence of secondary malignancies were similar in patients with HGBL and DLBCL (11% vs 11%, P = .830; 6.4% vs 11.4%, P = .844). Among patients in whom CAR T-cell therapy failed, the 1-year OS after failure was significantly higher in transformed than de novo DLBCL and HGBL (59% vs 32% vs 11%, <0.0004). Earlier use of CAR T-cell therapy may improve the outcome of HGBL. This trial was registered at www.clinicaltrials.gov as #NCT06339255.
引用
- Dodero A, Ceparano G, Casadei B, et al. Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis. Blood Adv. 2025. PMID: 40763273. doi:10.1182/bloodadvances.2025016117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。